Cancer Diagnostics Market will Likely Rise to US$168.6 Bn by 2020

Owing to the increase in the number of incidences of cancer and rise in the expenditure of healthcare sector, the global market for cancer diagnostics is expected to make a remarkable growth in the future years. Moreover, the technological advancement along with government initiatives and fund contribution that work in favor of the market are also factors estimated to fuel the growth of the market.

The major factors expected to drive the Cancer Diagnostics Market is the demand for cancer diagnosis mainly from colorectal cancer, lung cancer, and breast cancer patients. The consumption of tobacco products in emerging economies especially in BRICS nations is also adding to the growth and prevalence of lung cancer worldwide. Similarly, breast cancer diagnosis rate is seen to be higher in the Asia Pacific region as compared to the other regions of the world. However, the lack of skilled professionals in developing nations may act as a hindrance to the growth of cancer diagnostic market. Adding to that, there is lack of proper reimbursement in the emerging nations and this can also impede the market growth at a global level.

The global cancer diagnostics market is prognosticated to be worth US$168.6 bn by 2020 with a CAGR of 7.60%. The forecast period is set to 2014 to 2020 and is anticipated to be increasing from US$100.9 bn as per the 2013 records.

Request to View Sample of Report –

The global cancer diagnostics market is categorized on the basis of applications and methods. Based on segmentation by application, the market is classified into Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Kidney Cancer, Colorectal Cancer (CRC), Breast Cancer, and Blood Cancer. On the basis of method, the cancer diagnosis market is differentiated by Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy.

Tumor Biomarker tests are further classified into Prostate Specific Antigen Tests, Alpha-Fetoprotein (AFP) Tests, Circulating Tumor Cells (CTC) Tests, CA 19-9 Tests, EGFR Mutation Tests, CA 125 Tests, Carcinoembryonic Antigen (CEA) Tests, HER2 Tests, Anaplastic Lymphoma Kinase (ALK) Tests, BRCA Tests, and KRAS Mutation Tests.

Be the first to comment

Leave a Reply

Your email address will not be published.